Considerations for Combinations Beyond Progression in Upper GI Cancer
Experts discuss how microsatellite-stable (MSS) status in this case affects the expected benefit of pembrolizumab and whether its continued use beyond progression in combination with other agents would be considered.
Video Player is loading.
EP: 1.HER2- Upper GI Cancer
EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy
EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer
EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach
EP: 7.Megan’s Journey With HER2+ Upper GI Cancer
EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer
EP: 9.ADCs in HER2+ Gastric Cancer
EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
Now Viewing
EP: 11.Considerations for Combinations Beyond Progression in Upper GI Cancer
EP: 12.Exploring Next-Line Options in HER2- MSS Gastric Cancer
Video content above is prompted by the following:
- How does the MSS status in this case affect the expected benefit of pembrolizumab, and would you consider its continued use beyond progression in combination with other agents?
Recent Videos
Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
Physician Assistant Perspectives: Importance of Patient Shared Decision-Making and Multidisciplinary Team Approach in R/R FL
Physician Assistant Perspectives: Aligning Patient Goals in R/R FL and Navigating Third-Line Treatment Options
Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Neurological Toxicity Recognition: ICANS Assessment and Management
Essential Patient and Caregiver Education for Tarlatamab Treatment Success
Looking Ahead in R/R FL: Unmet Needs and What’s Next
Related Content
